Brokerages Set Pulmonx Corporation (NASDAQ:LUNG) PT at $5.58

Pulmonx Corporation (NASDAQ:LUNG) has received a consensus recommendation of “Hold” from the seven research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $5.5833.

Several research analysts have commented on LUNG shares. Wall Street Zen lowered Pulmonx from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. D. Boral Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Pulmonx in a research report on Thursday, April 30th. Finally, Canaccord Genuity Group cut their price objective on Pulmonx from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC raised its position in Pulmonx by 4.9% in the third quarter. ADAR1 Capital Management LLC now owns 214,497 shares of the company’s stock valued at $347,000 after purchasing an additional 10,000 shares during the period. Jain Global LLC increased its position in shares of Pulmonx by 62.9% during the fourth quarter. Jain Global LLC now owns 30,566 shares of the company’s stock worth $68,000 after acquiring an additional 11,800 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Pulmonx by 95.8% during the third quarter. SG Americas Securities LLC now owns 24,863 shares of the company’s stock worth $40,000 after acquiring an additional 12,166 shares during the last quarter. Cerity Partners LLC purchased a new stake in shares of Pulmonx during the fourth quarter worth about $27,000. Finally, Opal Capital LLC purchased a new stake in shares of Pulmonx during the fourth quarter worth about $29,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

Pulmonx Stock Performance

Shares of LUNG opened at $1.65 on Wednesday. The company has a current ratio of 4.91, a quick ratio of 4.04 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $69.70 million, a P/E ratio of -1.27 and a beta of 0.28. The stock’s fifty day simple moving average is $1.36 and its 200 day simple moving average is $1.67. Pulmonx has a twelve month low of $1.13 and a twelve month high of $3.88.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, April 29th. The company reported ($0.33) earnings per share for the quarter, hitting the consensus estimate of ($0.33). Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%.The business had revenue of $20.59 million for the quarter, compared to analyst estimates of $20.43 million. On average, equities research analysts forecast that Pulmonx will post -1.13 earnings per share for the current year.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.